Abbott Laboratories Gains FDA Clearance for CardioMEMS System Updates and Plans App Launch
Abbott Laboratories (NYSE:ABT) has secured U.S. Food and Drug Administration clearance to expand features for its CardioMEMS HF System. Alongside the regulatory approval, the healthcare company plans to launch its CardioGuide HF app and Dynamic Treatment Plan later this year. Shares of the company rose 1.13% to $99.60 following the update.
The expanded regulatory approval and digital software rollout combine medical hardware enhancements with new digital tools. These additions aim to boost patient engagement and assist clinicians in managing heart failure care.
Investors and market participants should monitor the upcoming rollout of the digital application later this year, along with potential impacts on product adoption, reimbursement coverage, and future revenue growth.
Key points
- Abbott Laboratories received FDA clearance to expand features on its CardioMEMS HF System.
- The company plans to roll out the CardioGuide HF app and Dynamic Treatment Plan later this year.
- The new digital tools are designed to improve patient engagement and clinician heart failure management.
- Shares of Abbott Laboratories traded up 1.13% at $99.60.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What FDA clearance did Abbott Laboratories receive?
Abbott Laboratories received FDA clearance to expand features for its CardioMEMS HF System.
What is the CardioGuide HF app?
CardioGuide HF is a digital app and Dynamic Treatment Plan that Abbott is launching later this year to aid patient engagement and clinician management of heart failure.
When will Abbott roll out the CardioGuide HF app?
Abbott plans to roll out the CardioGuide HF app and Dynamic Treatment Plan later this year.